Spectral Medical Announces Fourth Quarter and Fiscal 2022 Results and Provides Corporate Update

2 years ago

Reports significant enhancements to accelerate Tigris patient enrollment including appointment of new Contract Research Organization Management to host Investor Day…

Jushi Holdings Inc. to Report Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023

2 years ago

BOCA RATON, Fla., March 24, 2023 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF),…

Abeona Therapeutics Announces New Employee Inducement Grants

2 years ago

NEW YORK and CLEVELAND, March 24, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted…

Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

2 years ago

Reprioritized product portfolio to focus on IV-administered, self-amplifying RNA medicinesOn track to submit IND for ONCR-021 in mid-2023Preclinical data featured…

HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023

2 years ago

BOSTON, March 24, 2023 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing novel therapeutics to address mechanisms of metastasis,…

Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update

2 years ago

-- Enrollment Nearing Completion in Human Acellular Vessel™ (HAV™) Phase 2/3 Trial in Vascular Trauma and Phase 3 Trial in…

23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease

2 years ago

Company teams up with Novartis on Lipoprotein(a) education for 23andMe customersSOUTH SAN FRANCISCO, Calif., March 24, 2023 (GLOBE NEWSWIRE) --…

Grace Breeding Reports 2022 Full-Year Financial Results

2 years ago

- Program developments throughout 2022, and, to date in 2023, bring Grace Breeding closer to offering crop solutions to farmers aligned…

89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock

2 years ago

SAN FRANCISCO, March 24, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the…

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

2 years ago

TREK-AD Phase 2b study of eblasakimab fully enrolled, topline data readout expected early July 2023Phase 2 proof-of-concept trial of farudodstat…